Trial Profile
Effect of Dapagliflozin, a Sodium Glucose Co-transporter 2 Inhibitor, on Vascular Functions in Patients With Type 2 Diabetes Compared to Gliclazide
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary) ; Gliclazide; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 11 Jun 2019 Results presented at the 79th Annual Scientific Sessions of the American Diabetes Association
- 09 Sep 2018 Status changed from recruiting to completed.
- 10 Aug 2017 Planned End Date changed from 1 Nov 2017 to 1 Dec 2017.